Chemagis Ltd.

Alexander Weisman

Joseph Kaspi

Oded Arad

Ori Lerman

Itai Adin

Oded Friedman

Boris Freger

Eliezer Adar

David Sondack

Yuri Futerman

Chaim Ashkenazi

Iosef Manascu

Rina Uzan

Tamir Fizitzki

Chalil Abu Gnim

A novel process for preparing (2&#x3b2;,3&#x3b1;,5&#x3b1;,16&#x3b2;,17&#x3b2;)-17-acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl) androstane, a known intermediate in the synthesis of the skeletal muscle relaxant rocuronium bromide, is disclosed.

Processes for the preparation of rocuronium bromide and intermediates thereof

The present invention provides a crystalline halobetasol propionate selected from the group consisting of halobetasol propionate having crystalline Form I characterized by power X-ray diffraction peak positions and intensities as set forth in Table 1 herein, halobetasol propionate having crystalline Form II characterized by power X-ray diffraction peak positions and intensities as set forth in Table 2 herein, halobetasol propionate having crystalline Form III characterized by power X-ray diffraction peak positions and intensities as set forth in Table 3 herein, halobetasol propionate having crystalline Form IV characterized by power X-ray diffraction peak positions and intensities as set forth in Table 4 herein, halobetasol propionate having crystalline Form V characterized by power X-ray diffraction peak positions and intensities as set forth in Table 5 herein, and halobetasol propionate having crystalline Form VI characterized by power X-ray diffraction peak positions and intensities as set forth in Table 6 herein.

Crystalline forms of halobetasol propionate

The invention provides a pharmaceutical composition for the treatment of dementia or Alzheimer's disease in which the active therapeutical agent is donepezil hydrochloride in an amorphous state.

Pharmaceutical compositions containing donepezil hydrochloride

Growing community of inventors

Kiryat-Ekron, Israel

Alexander Weisman